Kelsey Stephen Michael, an insider at Revolution Medicines Inc (RVMD), sold 278,600 shares of the company's stock on December 15, 2025, at a price of $76.82 per share. The total value of this transaction amounted to $21.40 million. Following this sale, Michael retains an equal number of shares in Revolution Medicines.
Revolution Medicines, a clinical-stage precision oncology company based in Redwood City, California, focuses on developing novel targeted therapies. The company's market capitalization stands at $14.8 billion, with a trailing twelve months (TTM) earnings per share (EPS) of -2.73. Revolution Medicines went public on February 13, 2020, and currently employs 700 full-time staff.
The upcoming earnings report is scheduled for August 4, 2026, with an estimated EPS of -1.76 and projected revenue of $0. This update provides insight into insider trading patterns, which can reflect various personal or financial motivations. While insider selling may raise questions, it does not inherently signal negative sentiment towards the company. Investors are encouraged to consider broader trends in insider activity rather than isolated transactions when evaluating such signals.